In the Know About Recurrence, Sarah Adams, MD
1 like1,414 views
The document discusses recurrent ovarian cancer. It notes that the chances of recurrence vary based on initial stage, with stage III having the highest risk. Symptoms of recurrence can include abdominal bloating or pain. Recurrence is typically diagnosed through physical exam, rising CA125 levels, or imaging. Treatment depends on platinum sensitivity, and may include surgery, chemotherapy, targeted therapies, or clinical trials. One study found that initiating treatment based on rising CA125 levels alone improved progression-free and overall survival compared to waiting for symptoms.
![Initial treatment: curative intent
Primary treatment:
– Debulking or cytoreductive surgery
– Chemotherapy
• Neo-adjuvant chemotherapy (chemotherapy before surgery)
• Primary adjuvant chemotherapy (chemotherapy after surgery)
[Maintenance therapy: ongoing chemotherapy to reduce the risk
of recurrence]](https://image.slidesharecdn.com/intheknowaboutrecurrencesarahadams-150819131917-lva1-app6891/85/In-the-Know-About-Recurrence-Sarah-Adams-MD-6-320.jpg)
![Initial treatment: curative intent
Primary treatment:
– Debulking or cytoreductive surgery
– Chemotherapy
• Neo-adjuvant chemotherapy (chemotherapy before surgery)
• Primary adjuvant chemotherapy (chemotherapy after surgery)
[Maintenance therapy: ongoing chemotherapy to reduce the risk
of recurrence]
Cancer surveillance:
• 3-month intervals for two years
• 4-month intervals for the third year
• 6-month intervals for up to 10 years](https://image.slidesharecdn.com/intheknowaboutrecurrencesarahadams-150819131917-lva1-app6891/85/In-the-Know-About-Recurrence-Sarah-Adams-MD-7-320.jpg)
In the Know About Recurrence, Sarah Adams, MD
- 1. Recurrent Ovarian Cancer Ovarian Cancer National Alliance Conference Sarah Adams, MD July 25, 2015
- 2. Outline 1. What are the chances that ovarian cancer will return after initial treatment? 2. What symptoms might suggest recurrent disease? 3. How is a recurrence diagnosed or confirmed? 4. *What treatment options are available and what factors affect decisions about which to choose? 5. *Are there benefits to enrolling in a clinical trial?
- 3. Ovarian cancer subtypes Most ovarian cancers arise from the lining of the ovary –the epithelial layer. Cancers arising from germ cells (eggs) or stromal cells are less common. In this presentation, I will focus on data about epithelial cancers (EOC).
- 4. Ovarian cancer subtypes Most ovarian cancers arise from the lining of the ovary –the epithelial layer. Cancers arising from germ cells (eggs) or stromal cells are less common. In this presentation, I will focus on data about epithelial cancers (EOC).
- 5. Initial treatment: curative intent Primary treatment: – Debulking or cytoreductive surgery – Chemotherapy • Neo-adjuvant chemotherapy (chemotherapy before surgery) • Primary adjuvant chemotherapy (chemotherapy after surgery)
- 6. Initial treatment: curative intent Primary treatment: – Debulking or cytoreductive surgery – Chemotherapy • Neo-adjuvant chemotherapy (chemotherapy before surgery) • Primary adjuvant chemotherapy (chemotherapy after surgery) [Maintenance therapy: ongoing chemotherapy to reduce the risk of recurrence]
- 7. Initial treatment: curative intent Primary treatment: – Debulking or cytoreductive surgery – Chemotherapy • Neo-adjuvant chemotherapy (chemotherapy before surgery) • Primary adjuvant chemotherapy (chemotherapy after surgery) [Maintenance therapy: ongoing chemotherapy to reduce the risk of recurrence] Cancer surveillance: • 3-month intervals for two years • 4-month intervals for the third year • 6-month intervals for up to 10 years
- 8. What are the chances that ovarian cancer will return after initial treatment?
- 9. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Approximate Percentage of Recurrence Stage I Stage II Stage III (optimal) Stage III (suboptimal) Stage IV Ovarian cancer recurrence
- 10. What symptoms might suggest recurrent disease?
- 11. Symptoms associated with ovarian cancer recurrence • Bloating, abdominal fullness, increased girth, indigestion • Pelvic pain • Change in bowel or bladder habits • Early satiety • Vaginal discharge or bleeding • Pain with intercourse • Lymphedema / leg swelling • Shortness of breath • Nausea, vomiting *Any new or persistent symptoms should be reported to your oncologist
- 12. How is a recurrence diagnosed or confirmed?
- 13. Physical exam • Physical exam – Evaluation of lymph nodes – Chest exam for pleural fluid – Abdominal exam for masses, fullness, fluid accumulation, pain – Pelvic exam for masses or nodularity – Extremities for swelling, tenderness, range of motion • 35% who presented with symptoms had a normal physical exam
- 14. CA125 • 61% of women diagnosed with recurrence based on an elevated CA125 level – Rises in CA125 may precede symptomatic relapse by a median of 4.5 months (range 0.5-29.5 months) – Doubling of CA125 has a sensitivity of 86% and a specificity of 91% for detecting progression. – A second confirmatory value reduces the false-negative rate to <2%. – Even a rise within the normal range is associated with a high risk of relapse.
- 15. Imaging • CT or MRI scan can be used to evaluate for recurrence – Imaging is indicated in response to new symptoms or a rise in CA125 – Sensitivity ranges from 40-93% – It may be difficult to detect peritoneal or serosal disease • PET sensitivity of 88-90% • Directed biopsy may be performed to confirm recurrence
- 16. What treatment options are available and what factors affect decisions about which to choose?
- 17. Treatment goals for recurrent disease • Recurrent ovarian cancer is unlikely to be cured with currently available chemotherapeutics, radiation or surgery. Goal of treatment in the setting of recurrent disease is to prolong disease-free and overall survival and to palliate symptoms • Options include surgery, chemotherapy, targeted therapeutics, immune therapy hormones, radiation, observation
- 18. Surgery • Secondary (or tertiary) debulking surgery – Rationale is based on benefit seen with primary debulking – Studies of secondary surgery are limited by patient selection Generally, surgery is reserved for women with: • Platinum-sensitive disease • Limited sites of recurrence • Long treatment-free intervals (>24 mos) • Absence of ascites • Good performance status • As with primary surgery, the best outcomes are seen in patients who can be optimally debulked • Minimally invasive options (robotic or laparoscopic surgery) may reduce morbidity for eligible women
- 19. Chemotherapy • Most patients respond to second-line chemotherapy • Response to second-line chemotherapy is predicted by: – Tumor type, size, and number of disease sites – Duration of response to previous platinum based regimen, platinum-free interval and TFI (most important) • TFI <12 mos: Response Rate 24-35% • TFI >12 mos: Response Rate 52-62%
- 20. Platinum sensitivity Most women with ovarian cancer receive a platinum drug (carboplatin, cisplatin, oxaloplatin) as part of their primary chemotherapy regimen. The time to recurrence after platinum treatment determines “platinum sensitivity” Response to platinum Likely secondary treatment Examples Platinum sensitive >6 months without recurrence Another platinum- based regimen Carboplatin alone or in combination with another drug Platinum resistant < 6 months until recurrence A non-platinum drug Doxil, Taxol, Gemzar, Topotecan Platinum refractory Failure to achieve remission A non-platinum drug Doxil, Taxol, Gemzar, Topotecan
- 21. Platinum sensitivity Most women with ovarian cancer receive a platinum drug (carboplatin, cisplatin, oxaloplatin) as part of their primary chemotherapy regimen. The time to recurrence after platinum treatment determines “platinum sensitivity” Response to platinum Likely secondary treatment Examples Platinum sensitive >6 months without recurrence Another platinum- based regimen Carboplatin, often in combination with another drug Platinum resistant < 6 months until recurrence A non-platinum drug Doxil, Taxol, Gemzar, Topotecan Platinum refractory Failure to achieve remission A non-platinum drug Doxil, Taxol, Gemzar, Topotecan
- 22. Platinum sensitivity Most women with ovarian cancer receive a platinum drug (carboplatin, cisplatin, oxaloplatin) as part of their primary chemotherapy regimen. The time to recurrence after platinum treatment determines “platinum sensitivity” Response to platinum Likely secondary treatment Examples Platinum sensitive >6 months without recurrence Another platinum- based regimen Carboplatin alone or in combination with another drug Platinum resistant < 6 months until recurrence A non-platinum drug Doxil, Taxol, Gemzar, Topotecan Platinum refractory Failure to achieve remission A non-platinum drug Doxil, Taxol, Gemzar, Topotecan
- 23. Platinum sensitivity Most women with ovarian cancer receive a platinum drug (carboplatin, cisplatin, oxaloplatin) as part of their primary chemotherapy regimen. The time to recurrence after platinum treatment determines “platinum sensitivity” Response to platinum Likely secondary treatment Examples Platinum sensitive >6 months without recurrence Another platinum- based regimen Carboplatin alone or in combination with another drug Platinum resistant < 6 months until recurrence A non-platinum drug Doxil, Taxol, Gemzar, Topotecan Platinum refractory Failure to achieve remission A non-platinum drug Doxil, Taxol, Gemzar, Topotecan
- 24. Study (number of patients) Agents Response Rate (%) Progression free survival (months) Overall survival (months) ICON 4 (802) Carboplatin Carboplatin + Taxol 54% 66% 9 12* 24 29* AGO (366) Carboplatin Carboplatin + Gemcitabine 31% 47% 5.8 8.6* 17.3 18 CALYPSO (976) Carboplatin + Taxol Carboplatin + Doxil 9.4 11.3* 31.5 OCEANS (484) Carboplatin + Gemcitabine Carbo+Gem+Avastin 57% 79% 8.4 12.4* 35.2 33.3 Clinical trials in platinum-sensitive patients with recurrent ovarian cancer Coleman R, et al. Nat Rev Clin Oncol 5 Feb 2013 Response rates to second-line treatment are high among women with platinum – sensitive disease.
- 25. Study (number of patients) Agents Response Rate (%) Progression free survival (months) Overall survival (months) ICON 4 (802) Carboplatin Carboplatin + Taxol 54% 66% 9 12* 24 29* AGO (366) Carboplatin Carboplatin + Gemcitabine 31% 47% 5.8 8.6* 17.3 18 CALYPSO (976) Carboplatin + Taxol Carboplatin + Doxil 9.4 11.3* 31.5 OCEANS (484) Carboplatin + Gemcitabine Carbo+Gem+Avastin 57% 79% 8.4 12.4* 35.2 33.3 Clinical trials in platinum-sensitive patients with recurrent ovarian cancer Coleman R, et al. Nat Rev Clin Oncol 5 Feb 2013 Platinum-sensitive patients are usually treated with another platinum-containing regimen – often carboplatin in combination with a second drug.
- 26. Agent Response Rate (%) Progression free survival (months) Overall survival (months) Side effects Doxil 10-20% 3-4 10-12 Hand-foot syndrome, mucositis Topotecan 12-18% 3-4 10-12 Myelosuppression Taxotere 22% 3.5 12.7 Myelosuppression Gemzar 15% 4-5 11.8-12.7 Myelosuppression Etoposide 6-27% 4-5 10-11 Myelosuppression Taxol 10-30% 4-6 13 Myelosuppression, neuropthy Avastin 21% 4.7 17 Hypertension, blood clots Most-frequently used agents in platinum-resistant disease Coleman R, et al. Nat Rev Clin Oncol 5 Feb 2013 Because of the more limited prognosis associated with platinum-resistant disease, reducing toxicity becomes a primary goal, and typically single agent protocols are used.
- 27. Targeted agents • Advantages: – Different (often more limited) toxicity profile – May be active in chemotherapy resistant disease – Better understood mechanism of action • Bevacizumab (Avastin): – blocks blood vessel formation in tumors – response rate greater than 20% (6 mo PFS 28-40%) • PARP-inhibitors: – block single-strand DNA repair – best response is among women with BRCA gene mutations – response rates as high as 33% in recurrent EOC
- 28. Hormone therapy • Advantages: – Lower toxicity – Oral administration • Tamoxifen: – Response rate of 17-20% among women with recurrent ovarian cancer • Fulvestrant (selective estrogen receptor modulator) – Maintained disease stability in 50-64% of patients, 30% at 90 days • Aromatase Inhibitors – Modest objective RR of 8-15%, stability in 19-24%
- 29. Immune therapy • Advantages: – Adaptive effects and potential for long-term benefit – Toxicity profile is different than cytotoxic chemotherapy • Currently available primarily through clinical trials • Examples: – Cancer vaccines – T cell therapy – Immune checkpoint blockade antibodies
- 30. Radiotherapy • Whole abdominal radiation therapy is associated with significant toxicity and has limited efficacy in the treatment of recurrent disease • Localized radiation may be effective – Good for symptom control – Best for deposits in the pelvis, at the vaginal vault, on the abdominal wall. – Median remission of 4.8 months.
- 31. Observation - When should treatment be initiated? • Many oncologists believe that early diagnosis and treatment of recurrent disease improves outcomes for women with ovarian cancer – Better surgical outcomes – Smaller tumors are more susceptible to chemotherapeutics – Better symptom control
- 32. Observation - When should treatment be initiated? • Many oncologists believe that early diagnosis and treatment of recurrent disease improves outcomes for women with ovarian cancer – Better surgical outcomes – Smaller tumors are more susceptible to chemotherapeutics – Better symptom control Rustin GJ,et al, Lancet 2010 • 2010 European study: Does earlier treatment improve survival?
- 33. 1442 women with ovarian cancer • complete remission • normal CA125 levels • platinum-based primary chemotherapy. Underwent CA125 testing every 3 months 529 experienced a doubling in CA125 and were randomized 265 assigned to the “early treatment” group • Clinicians and patients notified of the rise in CA125 • Treatment initiated 264 assigned to “delayed treatment” group • Clinicians and patients blinded to CA125 levels • Treatment initiated when symptoms or clinical findings suggested recurrence Evaluated for the length of treatment-free intervals, overall survival, and quality of life When should treatment be initiated? 2010 European study: Does earlier treatment improve survival? Rustin GJ,et al, Lancet 2010
- 34. 1442 women with ovarian cancer • complete remission • normal CA125 levels • platinum-based primary chemotherapy. Underwent CA125 testing every 3 months 529 experienced a doubling in CA125 and were randomized 265 assigned to the “early treatment” group • Clinicians and patients notified of the rise in CA125 • Treatment initiated 264 assigned to “delayed treatment” group • Clinicians and patients blinded to CA125 levels • Treatment initiated when symptoms or clinical findings suggested recurrence Evaluated for the length of treatment-free intervals, overall survival, and quality of life When should treatment be initiated? Rustin GJ,et al, Lancet 2010 2010 European study: Does earlier treatment improve survival?
- 35. 1442 women with ovarian cancer • complete remission • normal CA125 levels • platinum-based primary chemotherapy. Underwent CA125 testing every 3 months 529 experienced a doubling in CA125 and were randomized 265 assigned to the “early treatment” group • Clinicians and patients notified of the rise in CA125 • Treatment initiated 264 assigned to “delayed treatment” group • Clinicians and patients blinded to CA125 levels • Treatment initiated when symptoms or clinical findings suggested recurrence Evaluated for the length of treatment-free intervals, overall survival, and quality of life When should treatment be initiated? Rustin GJ,et al, Lancet 2010 2010 European study: Does earlier treatment improve survival?
- 36. 1442 women with ovarian cancer • complete remission • normal CA125 levels • platinum-based primary chemotherapy. Underwent CA125 testing every 3 months 529 experienced a doubling in CA125 and were randomized 265 assigned to the “early treatment” group • Clinicians and patients notified of the rise in CA125 • Treatment initiated 264 assigned to “delayed treatment” group • Clinicians and patients blinded to CA125 levels • Treatment initiated when symptoms or clinical findings suggested recurrence Evaluated for the length of treatment-free intervals, overall survival, and quality of life When should treatment be initiated? Rustin GJ,et al, Lancet 2010 2010 European study: Does earlier treatment improve survival?
- 37. 1442 women with ovarian cancer • complete remission • normal CA125 levels • platinum-based primary chemotherapy. Underwent CA125 testing every 3 months 529 experienced a doubling in CA125 and were randomized 265 assigned to the “early treatment” group • Clinicians and patients notified of the rise in CA125 • Treatment initiated 264 assigned to “delayed treatment” group • Clinicians and patients blinded to CA125 levels • Treatment initiated when symptoms or clinical findings suggested recurrence Evaluated for the length of treatment-free intervals, overall survival, and quality of life When should treatment be initiated? Rustin GJ,et al, Lancet 2010 2010 European study: Does earlier treatment improve survival?
- 38. • No difference in overall survival • Women in the early treatment group underwent more courses of chemotherapy • Delayed treatment was associated with better quality of life scores. Rustin GJ,et al, Lancet 2010 Results:
- 39. Are there benefits to enrolling in a clinical trial?
- 40. Standard health care vs. clinical trials • Standard health care: interventions designed solely to enhance the well-being of the patient that have a reasonable expectation of success • Research (Clinical trial): an activity designed to test a hypothesis, permit conclusions to be drawn, develop or contribute to generalizable knowledge
- 41. Clinical Trials • Oversight and protection of subjects – Institutional Review Boards (IRB) • Protect the rights and welfare of research subjects • Include members of the community – Informed consent • Benefits, risks and discomforts • Alternatives to participation • Must be voluntary and un-coerced • Strategies to optimize results – Randomization • Process by which participants are assigned to treatment groups • Placebo control is optimal to evaluate new treatments – Blinding • Single-blind: treating physician knows but patient doesn’t • Double-blind: neither the treating physician nor the patient knows
- 42. Goals of clinical trials Phase I Trials: – Safety and tolerability – Uncontrolled, unblinded – Not randomized
- 43. Goals of clinical trials Phase I Trials: – Safety and tolerability – Uncontrolled, unblinded – Not randomized Phase II Trials: – Dose finding; dose-dependent efficacy – Controlled or uncontrolled; may be blinded or unblinded – Randomized or not randomized
- 44. Goals of clinical trials Phase I Trials: – Safety and tolerability – Uncontrolled, unblinded – Not randomized Phase II Trials: – Dose-finding; dose-dependent efficacy – Controlled or uncontrolled; may be blinded or unblinded – Randomized or not randomized Phase III Trials: – therapeutic ratio (and continued safety) (Drug x compared to drug y) – Control is placebo or standard of care. – Blinded – Randomized
- 45. Goals of clinical trials Phase I Trials: – Safety and tolerability – Uncontrolled, unblinded – Not randomized Phase II Trials: – Dose-finding; dose-dependent efficacy – Controlled or uncontrolled; may be blinded or unblinded – Randomized or not randomized Phase III Trials: – therapeutic ratio (and continued safety) (Drug x compared to drug y) – Control is placebo or standard of care. – Blinded – Randomized Phase IV Trials: post-marketing surveillance (safety)
- 46. Benefits of clinical trials • Additional benefits: – Oversight by a team of physicians, nurses, study personnel – both locally and often at a national level – Expanded options for treatment – Benefit to other women with ovarian cancer by advancing our understanding of treatment options and cancer biology Advantages Disadvantages Phase I trials Access to newest therapeutic agents Dose escalation may mean that a lower dose is given to early participants Usually not randomized or blinded Primary outcome is safety and tolerability Smaller studies, results may be available sooner May or may not be given with known active agents Phase III trials Protocol already tested in prior phase I/II with evidence of efficacy Often randomized Often blinded Often given with active agents; control arm is usually standard treatment Large scale studies – may take years to learn results
- 47. Questions to ask if you are considering enrolling in a clinical trial: • What is the scientific rationale for conducting the trial? • What are the objectives of the trial? • In what phase is the trial? How many participants will there be? • What are the eligibility requirements? • What is the intervention, and what is its duration and schedule? • What are the possible risks, side effects and benefits? • What medical tests and follow-up tests will participants undergo? How often? • What are the endpoints (measurable outcomes that indicate an intervention’s effectiveness)? • Who is sponsoring the trial? • What is the contact information to inquire about the trial?
- 48. Summary
- 49. There are many options available to manage ovarian cancer recurrence • Several factors affect choice of treatment including the presence of symptoms, response to prior treatment, availability of a clinical trial, patient preference • Goal of treatment is to optimize quality of life and to prolong remission • For more information about available clinical trials: www.ocrf.org/clinicaltrials
- 50. Thank you – questions?
- 51. Principles governing clinical trials • Regulatory codes place the responsibility for the ethical conduct of research on the shoulders of researchers – Autonomy • Informed consent • Confidentiality • Comprehension • Voluntariness – Beneficience • Peer review to determine whether the risks are justified • Investigator and subject in the determination to participate – Justice • Selection of subjects is equitable
- 52. Examples of ongoing clinical trials in recurrent ovarian cancer www.clinicaltrials.gov search: ovarian cancer, phase I • Phase I: – Paclitaxel in combination with VS-6063 in women with advanced ovarian cancer Open- label, multicenter, dose-escalation trial of paclitaxel in combination with VS-6063, a focal adhesion kinase inhibitor, in patients with advanced ovarian cancer. This study is comprised of 2 parts: Phase I (Dose escalation) and Phase Ib (Expansion). The purpose of this study is to assess the safety (including the recommended phase II dose), the pharmacokinetics, and the anti-cancer activity of VS-6063 when administered in combination with paclitaxel. Pharmacodynamic effects will also be examined in tumor biopsies. • Primary outcome measures: safety, tolerability, adverse events and their frequency, duration and severity, establish the recommended phase II dose • Secondary outcome measures: evaluate the efficacy – response rate and progression-free survival; assess pharmacokinetics • Other outcome measures: evaluate biomarkers of VS-6063 activity; examine if tumor expression status correlates with response to VS-6063 therapy • Phase I/II: – Doxorubicine +BIBF 1120: to determine whether BIBF 1120 can be safely combined with Doxil and to determine the clinical activity (phase II) in women with platinum-resistant ovarian cancer • Primary outcome measures, phase I: To find the maximum tolerated dose to be used during phase II and to evaluate the safety and toxicity of BIBF 1120 combined with Doxil • Primary outcome measures, phase II: To assess response rate in women with recurrent ovarian cancer treated with BIBF 1120 and Doxil • Secondary outcome measures: progression free survival; clinical rate of benefit defined by the number of patients experiencing an objective response or a CA125 resposne or sustained stable disease.
- 53. • Phase III – Efficacy study of chemotherapy to treat ovarian cancer recurrence by prolonging the platinum free interval: Liposomal Doxorubicin vs Carboplatin/Paclitaxel in patients with ovarian cancer recurrence between 6 and 12 months after previous platinum based therapy: This study will test the hypothesis that the artificial prolongation of the platinum-free interval with a non- platinum treatment will improve the effectiveness of overall therapy in patients with ovarian cancer progression occurring 6-12 months after first-line treatment with a platinum-derivative. Participants will be randomized to receive either platinum-based chemotherapy or a non-platinum drug. • Primary outcome measures: overall survival • Secondary outcome measures: progression free survival; changes in quality of life; number of objective responses; worst grade toxicity for each patient • Estimated enrollment: 250 Examples of ongoing clinical trials in recurrent ovarian cancer www.clinicaltrials.gov search: ovarian cancer, phase III